P/E ratio for Cartesian Therapeutics (RNAC)
P/E ratio as of May 2024 (TTM): -82.3
According to Cartesian Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -82.3125. At the end of 2021 the company had a P/E ratio of -13.6.
P/E ratio history for Cartesian Therapeutics from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -13.6 | 209.32% |
| 2020 | -4.39 | 125.1% |
| 2019 | -1.95 | 113.42% |
| 2018 | -0.9141 | -70.09% |
| 2017 | -3.06 | -19.25% |
| 2016 | -3.78 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.